Overview

Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

Status:
Completed
Trial end date:
2011-04-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety and tolerability of single rising doses of etelcalcetide in hemodialysis patients with secondary hyperparathyroidism.
Phase:
Phase 1
Details
Lead Sponsor:
KAI Pharmaceuticals